Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 8, 2025
Event: Completion of the second and final closing of a private placement offering of Series C Convertible Preferred Stock and warrants.
Key Financial Metrics
Capital Raised (Second Closing): $1.65 million in gross proceeds.
Securities Issued (Second Closing): 1,650 shares of Series C Convertible Preferred Stock and warrants to purchase up to 5,631,404 shares of Common Stock.
Total Offering Size (Initial + Second Closing): 3,300 shares of Preferred Stock and warrants for up to 11,262,808 shares of Common Stock (200% of initial conversion).
Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide a clear value for these operational metrics.
Material Changes
This filing reports the finalization of a capital raise initiated on February 13, 2025. The Second Closing on April 8, 2025, mirrors the Initial Closing in terms of share count and proceeds, completing the total commitment of $3.30 million for the full offering.
Guidance, Outlook, and Risks
Management Commentary: The Company executed the Second Closing pursuant to the Securities Purchase Agreement dated February 13, 2025.
Regulatory Status: Securities were sold without registration under the Securities Act of 1933, relying on Section 4(a)(2) and Regulation D exemptions.
Future Issuance: Common Stock underlying the Preferred Stock and Warrants will be issued pursuant to the same exemption or Section 3(a)(9) of the Securities Act.
Outlook/Guidance: The filing text does not provide a clear value for future financial guidance or specific operational outlook beyond the completion of this financing.
Investor Verification Checklist
- Verify the total dilution impact of the 11,262,808 shares of Common Stock underlying the warrants and preferred stock conversion.
- Confirm the specific conversion price and exercise price of the Series C Preferred Stock and Warrants, which are not explicitly stated in this summary text.
- Review the full Securities Purchase Agreement for covenants, redemption rights, or liquidation preferences attached to the Series C Preferred Stock.
- Assess the Company's cash runway post-transaction given the $3.30 million total gross proceeds raised.